{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T06:16:53Z","timestamp":1786947413473,"version":"build-2736575974"},"reference-count":20,"publisher":"Wiley","issue":"7","license":[{"start":{"date-parts":[[2024,8,26]],"date-time":"2024-08-26T00:00:00Z","timestamp":1724630400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Drug and Alcohol Review"],"published-print":{"date-parts":[[2024,11]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Introduction<\/jats:title><jats:p>Women who use drugs, particularly those using anabolic\u2010androgenic steroids (AAS), encounter heightened social risks influenced by the legal status of AAS, varying regionally. In jurisdictions where AAS are legal, medical guidance and prescription are common, while in illegal regions, there are challenges associated with acquisition and safer usage. Therefore, we aimed to explore the experiences of women who use AAS in Australia, where these substances are criminalised, with a focus on the challenges they encounter in acquiring and using these drugs.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>We focused on data from six women in a broader study interviewing 15 AAS users. The data were subjected to iterative inductive analysis, resulting in two theme\u2010categories.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Women who use AAS face distinct challenges in accessing reliable suppliers, with men seemingly having \u2018easier\u2019 access. Women experience this disparity as increasing their vulnerability to unsafe products, further compounded by their lack of knowledge regarding these substances. Moreover, mislabelling and counterfeiting of female\u2010specific AAS substances is described to further compound these risks, reflecting the participants' expressed need for enhanced intervention and quality control in the AAS market.<\/jats:p><\/jats:sec><jats:sec><jats:title>Discussion and Conclusions<\/jats:title><jats:p>Ensuring product reliability, transparency and accountability are perceived as essential for the health and safety of women who use AAS. To address these issues, interventions should provide women with comprehensive drug checking services tailored to their health needs. \u2018Steroid literacy\u2019 must be an integral component, equipping women with knowledge to make informed decisions in the gendered AAS market.<\/jats:p><\/jats:sec>","DOI":"10.1111\/dar.13931","type":"journal-article","created":{"date-parts":[[2024,8,27]],"date-time":"2024-08-27T04:19:50Z","timestamp":1724732390000},"page":"1962-1966","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":22,"title":["\u201cThe compounds for females are really commonly faked!\u201d: Women's challenges in anabolic steroid acquisition and the place of drug checking interventions"],"prefix":"10.1111","volume":"43","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6177-0266","authenticated-orcid":false,"given":"Timothy","family":"Piatkowski","sequence":"first","affiliation":[{"name":"School of Applied Psychology Griffith University  Brisbane Australia"},{"name":"Griffith Centre for Mental Health Griffith University  Brisbane Australia"},{"name":"Queensland Injectors Voice for Advocacy and Action  Brisbane Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ingrid Amalia","family":"Havnes","sequence":"additional","affiliation":[{"name":"Division of Mental Health and Addiction Oslo University Hospital  Oslo Norway"},{"name":"Institute of Clinical Medicine, Faculty of Medicine University of Oslo  Oslo Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emma","family":"Kill","sequence":"additional","affiliation":[{"name":"Griffith Centre for Mental Health Griffith University  Brisbane Australia"},{"name":"Queensland Injectors Voice for Advocacy and Action  Brisbane Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1015-9379","authenticated-orcid":false,"given":"Monica J.","family":"Barratt","sequence":"additional","affiliation":[{"name":"Social Equity Research Centre and Digital Ethnography Research Centre RMIT University  Melbourne Australia"},{"name":"National Drug and Alcohol Research Centre, UNSW Sydney  Sydney Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2024,8,26]]},"reference":[{"key":"e_1_2_8_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.annepidem.2014.01.009"},{"key":"e_1_2_8_3_1","doi-asserted-by":"publisher","DOI":"10.1111\/add.16643"},{"key":"e_1_2_8_4_1","doi-asserted-by":"publisher","DOI":"10.1097\/JSM.0b013e3181fb5370"},{"key":"e_1_2_8_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugpo.2020.102876"},{"key":"e_1_2_8_6_1","doi-asserted-by":"publisher","DOI":"10.1080\/14659891.2016.1179806"},{"key":"e_1_2_8_7_1","doi-asserted-by":"publisher","DOI":"10.1177\/00914509241249292"},{"key":"e_1_2_8_8_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12889-022-13734-4"},{"key":"e_1_2_8_9_1","doi-asserted-by":"publisher","DOI":"10.3389\/fspor.2021.656413"},{"key":"e_1_2_8_10_1","doi-asserted-by":"publisher","DOI":"10.1177\/26338076231209044"},{"key":"e_1_2_8_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugpo.2023.104139"},{"key":"e_1_2_8_12_1","doi-asserted-by":"publisher","DOI":"10.1177\/1609406920955118"},{"key":"e_1_2_8_13_1","doi-asserted-by":"publisher","DOI":"10.1111\/add.13314"},{"key":"e_1_2_8_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0955-3959(02)00119-6"},{"key":"e_1_2_8_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0960-0760(02)00220-0"},{"key":"e_1_2_8_16_1","doi-asserted-by":"publisher","DOI":"10.1136\/bjsm.9.2.60"},{"key":"e_1_2_8_17_1","first-page":"1","article-title":"Androgenic\u2010anabolic steroids use among women: prevalence of use and intention to use among those with high\u2010intensity functional training practice","volume":"14","author":"Santos e Santos GB","year":"2023","journal-title":"J Subst Abus"},{"key":"e_1_2_8_18_1","doi-asserted-by":"publisher","DOI":"10.31128\/AJGP-04-22-6402"},{"key":"e_1_2_8_19_1","doi-asserted-by":"publisher","DOI":"10.1097\/MED.0000000000000822"},{"key":"e_1_2_8_20_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13011-016-0056-3"},{"key":"e_1_2_8_21_1","doi-asserted-by":"publisher","DOI":"10.1080\/2159676X.2021.1941210"}],"container-title":["Drug and Alcohol Review"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/dar.13931","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,6]],"date-time":"2024-11-06T11:58:16Z","timestamp":1730894296000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/dar.13931"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,26]]},"references-count":20,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2024,11]]}},"alternative-id":["10.1111\/dar.13931"],"URL":"https:\/\/doi.org\/10.1111\/dar.13931","archive":["Portico"],"relation":{},"ISSN":["0959-5236","1465-3362"],"issn-type":[{"value":"0959-5236","type":"print"},{"value":"1465-3362","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,8,26]]},"assertion":[{"value":"2023-11-20","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-08-01","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-08-26","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}